Core Insights - Artisan Small Cap Fund aims to invest in companies with franchise characteristics, strong earnings trajectories, and trading at a discount to estimated private market value [1] - The Fund experienced strong absolute returns in Q4 2025, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index, despite elevated volatility and shifting market sentiment [1] - For the full year 2025, the Fund generated strong results but underperformed compared to both indexes [1] - The market leadership in Q4 2025 shifted back to companies with durable profit cycles, and the firm plans to continue focusing on identifying profit cycles in franchise companies at reasonable valuations in 2026 [1] Company Highlights - Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company specializing in liquid biopsy tests for cancer detection from blood samples [2] - As of March 16, 2026, Guardant Health's stock closed at $87.18 per share, with a one-month return of -18.61% and a twelve-month gain of 98.81% [2] - Guardant Health has a market capitalization of $11.435 billion [2] - The Fund initiated new positions in Guardant Health during Q4 2025, recognizing its leadership in liquid biopsy diagnostics and its market-leading position in tumor-naïve minimal residual disease (MRD) testing [3] - Guardant Health is expanding into tumor-informed MRD testing to address a broader range of clinical needs and strengthen its position in the MRD landscape [3]

Core Viewpoint - PMV Pharmaceuticals, Inc. reported strong progress in its clinical trials and financial results for the year ended December 31, 2024, highlighting the advancement of its lead drug candidate, rezatapopt, in treating cancers with TP53 mutations [1][4]. Clinical Development - The pivotal Phase 2 portion of the PYNNACLE trial is advancing well, with enrollment on track and more than 90% of sites activated across multiple regions [3][5]. - An interim analysis of the Phase 2 monotherapy data is expected in mid-2025, with a New Drug Application submission anticipated by the end of 2026 [3][5]. - Enrollment has begun in a Phase 1b study at MD Anderson Cancer Center, evaluating rezatapopt in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with a TP53 Y220C mutation [2][6]. Financial Performance - As of December 31, 2024, the company reported cash, cash equivalents, and marketable securities totaling $183.3 million, providing a cash runway expected to last until the end of 2026 [5][12]. - The net loss for the year ended December 31, 2024, was $58.7 million, a decrease from a net loss of $69.0 million in 2023 [12][17]. - Research and development expenses increased to $58.5 million in 2024 from $55.9 million in 2023, primarily due to clinical expenses related to rezatapopt [12][17]. Research Highlights - The Phase 1 data of rezatapopt in advanced ovarian cancer showed a confirmed partial response in 7 out of 15 patients, with a median duration of response of seven months [6]. - In advanced breast cancer, 3 out of 8 patients achieved a confirmed partial response, indicating a favorable safety profile [6]. - A paper detailing the discovery of rezatapopt was published, emphasizing its role as a first-in-class small-molecule reactivator of the p53 Y220C mutant [6][9].